Redbiotec AG produces multi-component virus-like particles (VLPs) and protein complexes for the use as novel vaccines and biologics as well as drug targets. These protein assemblies are produced using Redbiotec’s proprietary protein co-expression platform (rePAX™ technology). The VLPs generated by our platform are similar to natural viruses, since they contain multiple different viral proteins, however, are not infectious. Our main focus is the generation of multi-component VLPs for development of vaccines to prevent influenza flu, HPV induced cancer and other viral diseases. Redbiotec AG was founded in 2006 as spin-off from the ETH Zürich and is located in the biotech center Zürich in Switzerland. For more information please visit www.redbiotec.ch.
Research & Education